4.6 Article

Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term

期刊

ACTA NEUROPATHOLOGICA
卷 135, 期 1, 页码 65-83

出版社

SPRINGER
DOI: 10.1007/s00401-017-1792-9

关键词

Parkinson's disease; Alpha-synuclein; Aggregates; Spreading; Neurodegeneration; Propagation; Olfactory bulb

资金

  1. Van Andel Research Institute
  2. Peter C. and Emajean Cook Foundation
  3. National Institutes of Health (R21) [5R21NS093993-02]
  4. R01 grant from the National Institutes of Health [1R01DC016519-01]
  5. Penn Morris K. Udall Parkinson's Disease Research Center of Excellence [P50 NS053488]
  6. Penn AD Core Center [P30 AG10124, P01 AG17586]
  7. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS088322, R21NS093993, P50NS053488] Funding Source: NIH RePORTER
  8. NATIONAL INSTITUTE ON AGING [P01AG017586, P30AG010124] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC016519] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Parkinson's disease is characterized by degeneration of substantia nigra dopamine neurons and by intraneuronal aggregates, primarily composed of misfolded alpha-synuclein. The alpha-synuclein aggregates in Parkinson's patients are suggested to first appear in the olfactory bulb and enteric nerves and then propagate, following a stereotypic pattern, via neural pathways to numerous regions across the brain. We recently demonstrated that after injection of either mouse or human alpha-synuclein fibrils into the olfactory bulb of wild-type mice, alpha-synuclein fibrils recruited endogenous alpha-synuclein into pathological aggregates that spread transneuronally to over 40 other brain regions and subregions, over 12 months. We previously reported the progressive spreading of alpha-synuclein aggregates, between 1 and 12 months following alpha-synuclein fibril injections, and now report how far the pathology has spread 18- and 23-month post-injection in this model. Our data show that between 12 and 18 months, there is a further increase in the number of brain regions exhibiting pathology after human, and to a lesser extent mouse, alpha-synuclein fibril injections. At both 18 and 23 months after injection of mouse and human alpha-synuclein fibrils, we observed a reduction in the density of alpha-synuclein aggregates in some brain regions compared to others at 12 months. At 23 months, no additional brain regions exhibited alpha-synuclein aggregates compared to earlier time points. In addition, we also demonstrate that the induced alpha-synucleinopathy triggered a significant early neuron loss in the anterior olfactory nucleus. By contrast, there was no loss of mitral neurons in the olfactory bulb, even at 18 month post-injection. We speculate that the lack of continued progression of alpha-synuclein pathology is due to compromise of the neural circuitry, consequential to neuron loss and possibly to the activation of proteolytic mechanisms in resilient neurons of wild-type mice that counterbalances the spread and seeding by degrading pathogenic alpha-synuclein.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据